Brief: Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate

Ipsen SA

11/07/2024 06:06

July 11 (Reuters) - Ipsen SA  IPN.PA :
    * IPSEN AND FORESEEN BIOTECHNOLOGY ANNOUNCE EXCLUSIVE GLOBAL
LICENSING AGREEMENT FOR ANTIBODY-DRUG CONJUGATE WITH
FIRST-IN-CLASS POTENTIAL
    * EXCLUSIVE GLOBAL RIGHTS SECURED FOR DEVELOPMENT,
MANUFACTURE AND
COMMERCIALIZATION OF FS001, COMPLETING FINAL STAGES OF
PRE-CLINICAL DEVELOPMENT WITH FIRST-IN-CLASS POTENTIAL
    * FS001 TARGETS A NOVEL TUMOR ASSOCIATED ANTIGEN, HIGHLY
EXPRESSED
ACROSS A RANGE OF SOLID TUMORS, IDENTIFIED THROUGH APPLICATION
OF FORESEEN'S PROPRIETARY PROTEOMIC PLATFORMS
    * PRECLINICAL EFFICACY OF FS001 WAS DEMONSTRATED IN
MULTI-DRUG
RESISTANT CANCER MODELS
    * UNDER TERMS OF AGREEMENT, IPSEN WILL ASSUME RESPONSIBILITY
FOR
PHASE I PREPARATION ACTIVITIES, INCLUDING SUBMISSION OF
INVESTIGATIONAL NEW DRUG (IND) APPLICATION
    * FORESEEN BIOTECHNOLOGY IS ELIGIBLE TO RECEIVE UP TO
$1.03BN
COMPRISING UPFRONT, DEVELOPMENT, REGULATORY AND COMMERCIAL
MILESTONE PAYMENTS, AND TIERED ROYALTIES ON GLOBAL SALES,
CONTINGENT UPON SUCCESSFUL DEVELOPMENT AND REGULATORY APPROVALS
    * IPSEN WILL ASSUME RESPONSIBILITY FOR ALL SUBSEQUENT
CLINICAL-DEVELOPMENT, MANUFACTURING, AND GLOBAL
COMMERCIALIZATION ACTIVITIES

Source text for Workspace:  urn:newsml:reuters.com:*:nGNXdnR80
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))